Revolution Medicines, Inc.
RVMD
Rang in Aktien
#619
Revolution Medicines, Inc. is a precision oncology firm operating in the... Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.
Aktienkurs
$182.91
Zuletzt synchronisiert: 2026-10-19
Marktkapitalisierung
$39.20B
Veränderung (1 Tag)
2.78%
Veränderung (1 Jahr)
238.66%
Land
US
Handel Revolution Medicines, Inc. (RVMD)
Kategorie
Healthcare
P/S-Verhältnis für Revolution Medicines, Inc. (RVMD)
P/S-Verhältnis zum October 2026 TTM: 0.00
Laut den neuesten Finanzberichten und dem Aktienkurs von Revolution Medicines, Inc. beträgt das aktuelle Kurs-Umsatz-Verhältnis (TTM) 0.00. Am Ende des Jahres 2023 lag das P/S-Verhältnis bei 280.24.
P/S-Verlauf für Revolution Medicines, Inc. von 2017 bis 2026
P/S-Verhältnis zum Jahresende
| Jahr | P/S-Verhältnis | ändert |
|---|---|---|
| 2026 (TTM) | 0.00 | -100.00% |
| 2024 | 0.00 | -100.00% |
| 2023 | 280.24 | 416.25% |
| 2022 | 54.28 | -12.94% |
| 2021 | 62.35 | 1.65% |
| 2020 | 61.34 | 191.22% |
| 2019 | 21.06 | -59.70% |
| 2018 | 52.27 | 0.00% |
| 2017 | 0.00 | 0.00% |
P/S-Verhältnis für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | P/S-Verhältnis | P/S-Verhältnis-Differenz | Land |
|---|---|---|---|
| 10.02 | - |
US
|
|
| 40.55 | - |
US
|
|
| 3.96 | - |
AU
|
|
| - | - |
CH
|
|
| 10.15 | - |
NL
|
